Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 21 analyst ratings
Hold
Strong Buy 14%
Buy 33%
Hold 38%
Sell 14%
Strong Sell 0%

Bulls say

ResMed's operating margin improved by 80 basis points year-over-year, primarily due to gross margin expansion, which saw an increase of 230 basis points year-over-year linked to pricing strategies, manufacturing efficiencies, and declining component costs. In addition, the company reported respiratory sales in the Americas of $749 million, marking a 12% increase, while the rest of the world saw a growth of 8% in respiratory sales, demonstrating strong demand amid a growing market for sleep apnea treatment. Furthermore, improvements in gross margins to 59.2%, supported by operational efficiencies and a favorable product mix, coupled with a positive outlook on CPAP patient growth, indicate significant potential for enhanced profitability in the upcoming year.

Bears say

ResMed's gross margin remained flat sequentially, indicating potential challenges in maintaining profitability amid competitive pressures. The company's organic revenue growth has decelerated, dropping to 10% in F2Q25 from 11% in the prior quarter, raising concerns about its ability to maintain market position. Additionally, the anticipated impact of GLP-1 weight loss drugs is expected to create headwinds, with lowered earnings estimates suggesting continued downward pressures on revenue growth and margins in the upcoming fiscal years.

ResMed (RMD) has been analyzed by 21 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 33% recommend Buy, 38% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 21 analysts, ResMed (RMD) has a Hold consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $178.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $178.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.